Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1976 1
1983 1
1989 1
1997 1
2002 1
2005 2
2006 1
2007 2
2008 1
2009 2
2010 3
2011 10
2012 11
2013 10
2014 6
2015 10
2016 10
2017 15
2018 17
2019 11
2020 17
2021 20
2022 18
Text availability
Article attribute
Article type
Publication date

Search Results

146 results
Results by year
Filters applied: . Clear all
Page 1
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, Sato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: tamiya m. Eur J Cancer. 2021 Dec;159:144-153. doi: 10.1016/j.ejca.2021.09.041. Epub 2021 Nov 5. Eur J Cancer. 2021. PMID: 34749119
Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study.
Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, Yokoi T, Asao T, Tamiya M, Nakamura A, Yoshioka H, Haratani K, Teraoka S, Tokito T, Murakami S, Tamiya A, Itoh S, Yokouchi H, Watanabe S, Yamaguchi O, Tomii K, Yamamoto N. Fujimoto D, et al. Among authors: tamiya m. Eur J Cancer. 2021 Jun;150:63-72. doi: 10.1016/j.ejca.2021.03.016. Epub 2021 Apr 20. Eur J Cancer. 2021. PMID: 33892408
Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study.
Tsukita Y, Yamamoto T, Mayahara H, Hata A, Takeda Y, Nakayama H, Tanaka S, Uchida J, Usui K, Toyoda T, Tamiya M, Morimoto M, Oya Y, Kodaira T, Miyauchi E, Jingu K, Sugiura H. Tsukita Y, et al. Among authors: tamiya m. Radiother Oncol. 2021 Jul;160:266-272. doi: 10.1016/j.radonc.2021.05.016. Epub 2021 May 21. Radiother Oncol. 2021. PMID: 34023330
Nintedanib plus chemotherapy for non-small cell lung cancer with IPF: a randomized phase 3 trial.
Otsubo K, Kishimoto J, Ando M, Kenmotsu H, Minegishi Y, Horinouchi H, Kato T, Ichihara E, Kondo M, Atagi S, Tamiya M, Ikeda S, Harada T, Takemoto S, Hayashi H, Nakatomi K, Kimura Y, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakagawa K, Nakanishi Y, Okamoto I. Otsubo K, et al. Among authors: tamiya m. Eur Respir J. 2022 Mar 31:2200380. doi: 10.1183/13993003.00380-2022. Online ahead of print. Eur Respir J. 2022. PMID: 35361630
Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.
Sakata S, Otsubo K, Yoshida H, Ito K, Nakamura A, Teraoka S, Matsumoto N, Shiraishi Y, Haratani K, Tamiya M, Ikeda S, Miura S, Tanizaki J, Omori S, Yoshioka H, Hata A, Yamamoto N, Nakagawa K. Sakata S, et al. Among authors: tamiya m. Cancer Sci. 2022 Jan;113(1):221-228. doi: 10.1111/cas.15176. Epub 2021 Nov 7. Cancer Sci. 2022. PMID: 34704312 Free PMC article.
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D. Sato Y, et al. Among authors: tamiya m. Chest. 2022 Jun 1:S0012-3692(22)01068-6. doi: 10.1016/j.chest.2022.05.035. Online ahead of print. Chest. 2022. PMID: 35661746
Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.
Kunimasa K, Oka T, Hara S, Yamada N, Oizumi S, Miyashita Y, Kamada R, Funamoto T, Kawachi H, Kawamura T, Inoue T, Kuhara H, Tamiya M, Nishino K, Matsunaga T, Imamura F, Fujita M, Kumagai T. Kunimasa K, et al. Among authors: tamiya m. Lung Cancer. 2021 Mar;153:186-192. doi: 10.1016/j.lungcan.2020.10.021. Epub 2020 Nov 16. Lung Cancer. 2021. PMID: 33277055
Improvement strategies for successful next-generation sequencing analysis of lung cancer.
Kunimasa K, Matsumoto S, Nishino K, Nakamura H, Kuhara H, Tamiya M, Inoue T, Kawamura T, Kawachi H, Kuno K, Kimura T, Maniwa T, Okami J, Nakatsuka SI, Goto K, Kumagai T. Kunimasa K, et al. Among authors: tamiya m. Future Oncol. 2020 Aug;16(22):1597-1606. doi: 10.2217/fon-2020-0332. Epub 2020 Jun 3. Future Oncol. 2020. PMID: 32490705 Free article.
Structural requirements of cholenamide derivatives as the LXR ligands.
Saida-Tamiya K, Tamiya M, Sekiya G, Isobe K, Kitazawa T, Isaka N, Matsukawa A, Kawahara K, Komuro A, Ishiguro M. Saida-Tamiya K, et al. Among authors: tamiya m. Bioorg Med Chem Lett. 2019 Jun 1;29(11):1330-1335. doi: 10.1016/j.bmcl.2019.03.051. Epub 2019 Mar 30. Bioorg Med Chem Lett. 2019. PMID: 30952591
146 results